Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its plan to host a 2024 Summer Series of R&D webinars that highlight multiple clinical stage RNA interference (RNAi) based medicines that utilize the company’s proprietary Targeted RNAi Molecule (TRiMTM) platform. Each webinar in the Summer Series will focus on a specific therapeutic area and will feature presentations by Arrowhead team members about the company’s clinical candidates and external key opinion leaders, who will discuss the respective disease areas and treatment landscapes.
2024 Summer Series Schedule:
Muscular – ARO-DUX4 and ARO-DM1
Date: May 23, 2024
Time: 2:00 pm ET
Cardiometabolic – Plozasiran and zodasiran
Date: June 25, 2024
Time: TBD
Pulmonary – ARO-RAGE, ARO-MUC5AC, ARO-MMP7
Lesen Sie auch
Date: July 16, 2024
Time: TBD
Obesity/Metabolic – ARO-INHBE and one additional new program to be disclosed
Date: August 15, 2024
Time: TBD
Central Nervous System – Platform and pipeline updates
Date: September 25, 2024
Time: TBD
Christopher Anzalone, Ph.D., President and CEO at Arrowhead, said: “Arrowhead has made significant progress this year with our pipeline. We now have 14 investigational RNAi-based medicines in the clinic that leverage Arrowhead’s proprietary TRiMTM platform, four of which are in late-stage development. We are excited to launch the 2024 Summer Series of R&D webinars, which will provide an overview of the respective treatment landscapes, the biological rationale and preclinical data supporting each target, and our clinical development strategy for each pipeline program to be highlighted.”
Each event will be approximately 90 minutes in duration with live webcasts and replays available on the Events and Presentations page under the Investors section of the Arrowhead website. Registration links and additional details regarding times, agendas, and speakers will be provided on the Arrowhead website and social media channels prior to each event.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.